Impact of the COVID-19 pandemic on initiation of antihypertensive drugs in Sweden: an interrupted time series study.

Impact of the COVID-19 pandemic on initiation of antihypertensive drugs in Sweden: an interrupted time series study.

Publication date: Oct 16, 2024

Antihypertensives reduce the risk of myocardial infarction and stroke. Restrictions during the COVID-19 pandemic limited access to healthcare, which may have had a negative impact on drug prescribing. This study aimed to assess the effect of the COVID-19 pandemic on the initiation of antihypertensive drugs. Interrupted time series study using a segmented linear regression model. Swedish population assessed through linked national healthcare registers. 720 300 new users of antihypertensives. March 2020, COVID-19 pandemic onset. The change in the initiation of antihypertensives expressed as monthly cumulative incidence, stratified by age and sex. Data on dispensed prescriptions of diuretics, beta-blockers, calcium channel blockers, ACE inhibitors (ACEi) and angiotensin receptor blockers were extracted from the Swedish Prescribed Drug Register, from March 2018 to November 2021. Initiation (new use) was defined as having no previous dispensations before March 2019. Monthly cumulative incidence in March 2019-November 2021 was calculated as the number of patients initiating each drug class in each month divided by the population. The start of the pandemic was associated with an immediate drop in the initiation of any antihypertensive, but no sustained effects were observed, as the incidence continued to increase in the postinterruption period by +0. 02% each month in both sexes. The immediate drop was statistically significant for ACEi in both sexes and all antihypertensive classes except diuretics in patients >65 years. А significant postintervention trend change was observed for initiation of diuretics (+0. 013% overall), driven mainly by a significant increase in patients >65 years. Similar findings were also observed for diuretics in females (+0. 02%) and ACEi (+0. 03%) in patients >65 years. The pandemic had an immediate negative short-term effect, but we found no major long-term negative influence of the COVID-19 pandemic on initiation of any type of antihypertensive drugs.

Open Access PDF

Concepts Keywords
Antihypertensives Adult
Monthly Aged
Myocardial Aged, 80 and over
Swedish Angiotensin Receptor Antagonists
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Antihypertensive Agents
COVID-19
COVID-19
Diuretics
Diuretics
Drug Prescriptions
EPIDEMIOLOGIC STUDIES
Female
Humans
Hypertension
Hypertension
Male
Middle Aged
Pandemics
Practice Patterns, Physicians’
Registries
SARS-CoV-2
Sweden

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH myocardial infarction
disease MESH stroke
disease IDO intervention
disease MESH infection
disease MESH chronic conditions
disease MESH hypertension
disease MESH heart failure
disease MESH heart disease
drug DRUGBANK Coenzyme M
disease IDO blood
disease IDO host
disease IDO susceptibility
disease MESH death
drug DRUGBANK Oxygen
disease MESH morbidity
drug DRUGBANK Trestolone
drug DRUGBANK Pearl (hyriopsis cumingii)

Original Article

(Visited 1 times, 1 visits today)